Prelude Therapeutics (PRLD) Investor Presentation - Slideshow

Market Opportunity: • 70,000 patients with SMARCA4 mutation in the US/EU5 SMARCA2 Degrader 29 Driving The Programs to Key Milestones and Value Creation PRT2527 CDK9 • Present solid tumor data in 1H • RP2D in hematological malignancies in 2H • Present initial clinical data for hematological malignancies in 2H PRT1419 MCL1 PRT3645 CDK4/6 • Present initial clinical data in 2H SMARCA2 PROGRAM 2023 MILESTONES • Present solid tumor data in 1H • RP2D in solid tumors in early-2023 • RP2D in hematological malignanci ...